Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).
Chisari CG, Bianco A, Brescia Morra V, Calabrese M, Capone F, Cavalla P, Chiavazza C, Comi C, Danni M, Filippi M, Iaffaldano P, Lanzillo R, Lo Fermo S, Lucisano A, Lugaresi A, Lus G, Marfia GA, Marinelli F, Mirabella M, Moiola L, Perin C, Realmuto S, Toscano S, Trojano M, Vecchio D, Patti F; Italian MS Registry. Chisari CG, et al. Among authors: toscano s. Neurotherapeutics. 2023 Oct;20(6):1696-1706. doi: 10.1007/s13311-023-01415-y. Epub 2023 Aug 23. Neurotherapeutics. 2023. PMID: 37610702 Free PMC article.
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort.
D'Amico E, Chisari CG, Arena S, Zanghì A, Toscano S, Lo Fermo S, Maimone D, Castaing M, Sciacca S, Zappia M, Patti F. D'Amico E, et al. Among authors: toscano s. Front Neurol. 2019 Apr 10;10:337. doi: 10.3389/fneur.2019.00337. eCollection 2019. Front Neurol. 2019. PMID: 31024431 Free PMC article.
Pharmacoeconomics of synthetic therapies for multiple sclerosis.
D'Amico E, Chisari CG, Gitto L, Zanghì A, Toscano S, Patti F. D'Amico E, et al. Among authors: toscano s. Expert Opin Pharmacother. 2019 Aug;20(11):1331-1340. doi: 10.1080/14656566.2019.1615880. Epub 2019 May 15. Expert Opin Pharmacother. 2019. PMID: 31090469 Review.
An update on the safety of treating relapsing-remitting multiple sclerosis.
Chisari CG, Toscano S, D'Amico E, Lo Fermo S, Zanghì A, Arena S, Zappia M, Patti F. Chisari CG, et al. Among authors: toscano s. Expert Opin Drug Saf. 2019 Oct;18(10):925-948. doi: 10.1080/14740338.2019.1658741. Epub 2019 Aug 30. Expert Opin Drug Saf. 2019. PMID: 31429602 Review.
Rituximab for the treatment of multiple sclerosis: a review.
Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Chisari CG, et al. Among authors: toscano s. J Neurol. 2022 Jan;269(1):159-183. doi: 10.1007/s00415-020-10362-z. Epub 2021 Jan 8. J Neurol. 2022. PMID: 33416999 Free PMC article. Review.
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France.
Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, Bensa C, De Rossi N, Pelletier J, Cordioli C, Vukusic S, Moiola L, Kerschen P, Radaelli M, Théaudin M, Immovilli P, Casez O, Capobianco M, Ciron J, Trojano M, Stankoff B, Créange A, Tedeschi G, Clavelou P, Comi G, Thouvenot E, Battaglia MA, Moreau T, Patti F, De Sèze J, Louapre C; Musc-19; Covisep study groups. Sormani MP, et al. Ann Clin Transl Neurol. 2021 Aug;8(8):1738-1744. doi: 10.1002/acn3.51408. Epub 2021 Jul 7. Ann Clin Transl Neurol. 2021. PMID: 34240579 Free PMC article.
170 results